Global Bladder Cancer Treatment Market Was Valued at US$ XX Mn in 2017

This press release was orginally distributed by SBWire

London, London — (SBWIRE) — 11/10/2018 — Global Bladder Cancer Treatment Market was Valued at US$ XX Mn in 2017, Surge in Incidence of Bladder Cancer
Analyst Speak:

“The Global Bladder Cancer Treatment Market was valued around US$ XX Mn by 2017 and growing at a significant CAGR over seven years forecast period 2018-2024 owing to grow in incidence of bladder cancer around the globe.”

Precision Business Insights (PBI) in its report titled “Global Bladder Cancer Treatment Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2013-2017 and Forecast 2018-2024” assesses the market performance over seven years forecast period over 2018-2024. The report analyses the market value forecast and provides the strategic insights into the market driving factors, challenges that are hindering the market revenue growth over forecast period.

The global bladder cancer treatment market was valued at US$ XX Mn in 2017 and increasing at a significant CAGR over the forecast timeframe owing to surge in the incidence of bladder cancer, technological advancements in the treatment procedure, launch of newer therapeutics for the treatment, government initiatives to prevent the cancer and advanced healthcare services are expected to drive the global bladder cancer treatment market. However, high cost for the treatment, asymptomatic nature of the disease, adverse effects associated with the chemotherapy and radiotherapy are anticipated to hinder the revenue share of global bladder cancer treatment market.

Sample of this report is available upon request @

Global bladder cancer treatment market segmented on the basis of cancer type, drug class, distribution channel, and region

Immunotherapy Dominates the Global Bladder Cancer Treatment Market

Based on the drug class, global bladder cancer treatment market segmented into chemotherapy and immunotherapy. Immunotherapy dominated the global bladder cancer treatment market in 2017 and estimated to dominate over the forecast period owing to innovation of newer therapeutics by the companies, rise in awareness about the bladder cancer among the people, and patent filings by the market players are driving the growth of the market over the forecast years. However, a slow growth rate observed for the chemotherapy drugs due to patent expirations and entry of generics into the market.

North America Leads the Global Bladder Cancer Treatment Market

PBI’s global bladder cancer treatment market report analyses the market in different regions such as North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. According to regional analysis, North America accounted for larger revenue share through 2013-2017 and expected to dominate over 2018-2024 owing to advance healthcare system, presence of skilled professionals with high awareness about the bladder cancer, launch of innovative drugs into market, and rise in healthcare expenditure are propel the market. Asia Pacific bladder cancer treatment market projected to exhibit significant growth due to entry of market players into emerging countries such as India and China and development in healthcare infrastructure are boost the market

TOC of this report is available upon request @

Accelerated Approvals For The Drugs, and Favorable Reimbursement Scenario projected to drive the growth of the bladder cancer treatment market

Global bladder cancer treatment market players are actively investing on research and developments activities and providing assistance to the patient regarding their insurance coverage. Furthermore, favorable reimbursement scenario for the bladder cancer treatment drugs are driving the growth of the market. For instance. In 2017, AstraZeneca received U.S. FDA accelerated approval for Imfinzi (Durvalumab) for the treatment of bladder cancer

Key player’s profiles in the report are AstraZeneca plc. (U.K.), Bristol-Myers Squibb (U.S.), Celgene Corporation (U.S.), Eli Lilly and Company (U.S.), Co., AbbVie Inc., (U.S.), F. Hoffmann-La Roche (Switzerland), GlaxoSmithKline plc. (U.K.), Novartis AG (Switzerland), Pfizer Inc.( U.S.), and Sanofi (France)

Ask Analyst for Full Information about this report @

Detailed Segmentation

By Cancer Type
o Transitional cell bladder cancer
o Invasive bladder cancer
o Superficial bladder cancer
o Squamous cell bladder cancer
o Other rare types

By Drug Class
o Chemotherapy
o Alkylating agents
o Plant alkaloids
o Taxanes
o Anti-tumour Antibiotics
o Anti-metabolites
o Topoisomerase inhibitors
o Immunotherapy
o Tumor-targeting mAbs
o DC-Based immunotherapy
o Peptide- and DNA-based anticancer vaccines
o Immune stimulatory cytokines
o Immune modulatory mAbs
o Immuno suppressive metabolism Inhibitors
o Pattern recognition receptor Agonists
o Others

By Distribution Channel
o Hospital Pharmacies
o Retail Pharmacies
o Others

o North America
– U.S
– Canada

o Europe
– Germany
– France
– U.K
– Italy
– Spain
– Russia
– Poland
– Rest of Europe

o Asia-Pacific
– Japan
– China
– India
– Australia & New Zealand
– ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others)
– South Korea
– Rest of Asia-Pacific

o Latin America
– Brazil
– Mexico
– Argentina
– Venezuela
– Rest of Latin America

o Middle East and Africa (MEA)
– Gulf Cooperation Council (GCC) Countries
– Israel
– South Africa
– Rest of MEA

Get access to full summary @

About Precision Business Insights
Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.

Contact to Precision Business Insights,
Kemp House,
152 – 160 City Road,
London EC1V 2NX
Contact Person: Rajesh Babu
Role: Marketing Lead
Toll Free (US):+1-866-598-1553
Website @

For more information on this press release visit: